Open AccessA Review of Hyperuricaemia Management with Febuxostat: Dosage Titration, Monitoring and Maintenance
Author(s) -
Deepak Shankar Ray,
Tiny Nair,
Ramesh Dargad,
Verinder Dhar
Publication year - 2022
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2022/51970.15876
Subject(s) - febuxostat , medicine , intensive care medicine , kidney disease , context (archaeology) , uric acid , xanthine oxidase , gout , hyperuricemia , paleontology , biochemistry , chemistry , biology , enzyme
The burden of hyperuricaemia has been steadily increasing both globally and in India. The increasing number of hyperuricaemia- associated co-morbidities, such as Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Cardiovascular Diseases (CVD), and hypertension, implies that hyperuricaemia is associated with an increased risk of other chronic conditions or diseases. Despite the availability of several guidelines on hyperuricaemia, recommendations for appropriate titration of Urate Lowering Therapy (ULT) to achieve and maintain appropriate serum Uric Acid (sUA) levels in the Indian context are unclear. Another important challenge is the diagnosis and management of asymptomatic hyperuricaemia with ULT. This review summarises evidence-based discussion and review of literature by expert panellists on hyperuricaemia management with ULT, particularly with Xanthine Oxidase (XO) inhibitors. Based on the discussion, the experts developed a dose-titration algorithm for initiation and long-term management of hyperuricaemia with ULT, comprising febuxostat. The review also highlights some of the current challenges in hyperuricaemia management, which when addressed would benefit primary care physicians across the country for early screening and timely management of hyperuricaemia.